CAMBRIDGE, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) announced today that it will report third
quarter 2003 financial results on Wednesday, October 29, 2003 before the open
of U.S. financial markets. In connection with this announcement, TKT will
host a conference call and live audio webcast on Wednesday, October 29, 2003
at 10:00 a.m. Eastern Time to discuss its financial results, development
programs, and upcoming events.
Participants may access the financial conference call by dialing (973)
317-5319. In addition, an audio webcast will be available at http://www.tktx.com
under the Investor Information section. A replay will be available
approximately 2 hours after the conference call ends.
ASHG Event
In addition, TKT will hold an investor meeting on Friday, November 7, 2003
in conjunction with the American Society of Human Genetics (ASHG) Annual
Meeting in Los Angeles, California to discuss long-term Phase I/II data of
iduronate-2-sulfatase for the treatment of Hunter syndrome. The event will be
held from 8:30 - 9:30 a.m. Pacific Time on Friday, November 7, 2003 at the
Omni Los Angeles Hotel. In addition, an audio webcast may be accessed in the
Investor Information section of TKT's website. Please visit the Investor
Information section of TKT's web site for additional information and to
register in advance of the meeting.
About TKT
TKT is a biopharmaceutical company developing therapeutics for the
treatment of rare genetic diseases caused by protein deficiencies. The company
currently markets one product, Replagal(TM) (agalsidase alfa) for the
treatment of Fabry disease in the European Union and certain other countries.
TKT is headquartered in Cambridge, Massachusetts and has a majority-owned
subsidiary in Sweden, TKT Europe-5S AB, which is responsible for European
sales and marketing activities of Replagal. Additional information on TKT is
available on the company's website at http://www.tktx.com.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz of Transkaryotic Therapies,
Inc., Corporate Communications Specialist, +1-617-349-0205
|
